Figure 2

Molecular profiling of cytarabine-resistant cells revealed DCK deletion. (a) Genome-wide copy number analysis by exome sequencing was performed with 1280 Ara-C-resistant MOLM-13 and SHI-1 variants using respective parental cells as controls. Individual chromosomes are presented on the x axis and copy number ratios on the y axis. (b) Copy number analysis of AML patient samples 3443_3 (obtained before cytarabine treatment) and 3443_6 (obtained after cytarabine treatment) showed acquisition of homozygous deletion of DCK gene acquired after the patient was treated with two cycles of cytarabine-based therapy. (c, d) Microarray-based expression of DCK in MOLM-13 and SHI-1 parental and cytarabine-resistant variants.